May 11,2018

Hello Heart adds diabetes management, activity tracker to cardio health app

Hello Heart — maker of an app-driven platform designed to help employees manage hypertension, heart rate, and cardiovascular health — has announced the release of a new service for diabetes management. With the addition of the new diabetes management offering and other features, the Hello Heart app now hosts a range of tools to help individuals track various aspects of their health, including blood pressure, weight, blood sugar levels, and activity.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 16,2018

A good report card: Glooko

Diabetes management company Glooko announced the results of how endocrinologists and diabetes educators viewed CGM data collected through the company’s platform. After assessing CGM data from 10 Type 1 diabetes patients, these participants most endorsed the platform’s hypoglycemia and variance features, and more than 70 percent of the participating clinicians endorsed use of three or more of the platform’s CGM data features for patients.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 17,2018

Startup LifePlus announces noninvasive CGM wearable currently in testing

Yesterday, startup LifePlus exited stealth mode to reveal what it claims to be the first noninvasive continuous blood glucose monitoring multi-sensor wearable, called LifeLeaf. Although details are scarce on exactly how the technology works, the company said the product is being tested in five clinical trials around the world.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 01,2018

Insulet Establishes Two Significant Commercial Partnerships to Support its European Expansion

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has entered into partnerships with two highly-experienced diabetes distributors, Theras Group and Nordic Infucare, to provide full-service distribution of the Omnipod System in Italy and the Nordic markets beginning July 1st. These partnerships are key milestones for Insulet’s transition to direct operations in Europe to fully support its Omnipod System.

COLLABORATION PARTNERSHIP

#institution

#insulin pump

View Analyst & Ambassador Comments
Go to original news
May 01,2018

Tandem Diabetes Care to Present at the Deutsche Bank 43rd Annual Health Care Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA. The presentation will take place on Tuesday, May 8, 2018 at 10:40 AM Eastern Time (7:40 AM Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 03,2018

Insulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended March 31, 2018. The Company's first quarter 2018 revenue increased 21% to $123.6 million, compared to revenue of $101.7 million in the first quarter of 2017.

View Analyst & Ambassador Comments
Go to original news
May 03,2018

BD Announces Results for 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.

View Analyst & Ambassador Comments
Go to original news
May 03,2018

Insulet Achieves Key Milestones to Support its Transition to Direct Operations in Europe on July 1, 2018

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has achieved key milestones as it transitions to direct operations in Europe on July 1st. The Company has established a highly-talented European commercial team with deep knowledge of the diabetes landscape and extensive experience within the local markets. In addition, Insulet has partnered with two well respected and experienced companies - Teleperformance and HealthLink Europe - which will provide the full breadth of Insulet’s customer care, product support, distribution and logistics services.

View Analyst & Ambassador Comments
Go to original news
May 03,2018

Virta Health Aiming to Eradicate Type 2 Diabetes in Indiana with Announcement of New Two Commercial Partnerships

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) and other chronic metabolic diseases without the use of medications or surgery, today announced new commercial partnerships with Tippecanoe County Government, Indiana and the City of Lafayette, Indiana. The two alliances expand Virta Health’s presence in the region and provide access to the Virta Treatment as a fully-covered healthcare benefit to employees of Tippecanoe County Government and the City of Lafayette Government.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES